GlassScriptPhysician profile
Kenneth J Roth
NPI 1750475562
$3,354.02
in general payments reported to CMS, 2019-2025
42 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $181 · 2021: $606 · 2022: $585 · 2023: $590 · 2024: $561 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.03 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $465.76 | 2019-2025 | |
| Lilly USA, LLC | $289.73 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $287.84 | 2019-2025 | Viberzi, Linzess, Qulipta |
| Abbott Laboratories | $191.65 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Antares Pharma, INC. | $191.61 | 2020-2022 | |
| Novo Nordisk INC | $177.89 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $170.98 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.96 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $130.03 | 2019-2025 | Veozah |
| Dexcom, INC. | $107.69 | 2019-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $87.05 | 2022-2025 | Wavewriter Alpha Prime 16, Watchman |
| Janssen Pharmaceuticals, INC | $85.62 | 2019-2024 | Xarelto, Spravato |
| Medtronic, INC. | $85.41 | 2021-2024 | Intellis Adaptivestim |
| Amgen INC. | $81.85 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $72.50 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.